Zarębska-Michaluk, D.; Dobrowolska, K.; Flisiak, R.; Brzdęk, K.; Janczura, J.; Rzymski, P.; Brzdęk, M.
Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment. Cancers 2026, 18, 2079.
https://doi.org/10.3390/cancers18132079
AMA Style
Zarębska-Michaluk D, Dobrowolska K, Flisiak R, Brzdęk K, Janczura J, Rzymski P, Brzdęk M.
Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment. Cancers. 2026; 18(13):2079.
https://doi.org/10.3390/cancers18132079
Chicago/Turabian Style
Zarębska-Michaluk, Dorota, Krystyna Dobrowolska, Robert Flisiak, Kinga Brzdęk, Jakub Janczura, Piotr Rzymski, and Michał Brzdęk.
2026. "Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment" Cancers 18, no. 13: 2079.
https://doi.org/10.3390/cancers18132079
APA Style
Zarębska-Michaluk, D., Dobrowolska, K., Flisiak, R., Brzdęk, K., Janczura, J., Rzymski, P., & Brzdęk, M.
(2026). Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment. Cancers, 18(13), 2079.
https://doi.org/10.3390/cancers18132079